DRUGS - GENERIC Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.

August 23, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the top most highly correlated DRUGS - GENERIC stocks and the majority have fired a Buy signal as of today. CATALYST PHARMACEUTICAL PART (NASDAQ:CPRX), SYNTA PHARMACEUTICALS CORP (NASDAQ:SNTA), OREXIGEN THERAPEUTICS INC (NASDAQ:OREX), CELLDEX THERAPEUTICS INC (NASDAQ:CLDX), ISHARES NASDAQ BIOTECH INDX (NASDAQ:IBB), PAR PHARMACEUTICAL COS INC (NYSE:PRX) are all expected to be Up as the top stocks in the sector have fired Buy signals. Group rotation is a phenomenon where institutions exert buying or selling pressure in an industry group, pushing prices of the group higher or higher relative to the general market. An industry can often lead or lag the market, and the most highly correlated stocks (mirror closest to the overall move in that group) usually move in unison. The technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The chart below displays the correlation, beta and relative strength of the top most highly correlated stocks in the highlighted industry group:

     Symbol     Company                             Correlation     Beta        RelStr      Sector 
     CPRX       CATALYST PHARMACEUTICAL PART        0.18            1.06        0.9         DRUGS - GENERIC
     SNTA       SYNTA PHARMACEUTICALS CORP          0.55            2.93        1.06        DIAGNOSTIC SUBSTANCES
     OREX       OREXIGEN THERAPEUTICS INC           0.38            1.97        1           DRUG MANUFACTURERS/OT
     CLDX       CELLDEX THERAPEUTICS INC            0.63            1.47        1.04        DIAGNOSTIC SUBSTANCES
     IBB        ISHARES NASDAQ BIOTECH INDX         0.97            0.76        1           BIOTECHNOLOGY
     PRX        PAR PHARMACEUTICAL COS INC          0.71            0.55        0.99        DRUGS - GENERIC

We automatically calculate correlation to help find the stocks that most closely match their groups movement and generate powerful group consensus trading signals to profit from the herd mentality. When multiple stocks in a group turn at the same time and the rotation of that group is confirmed, an explosive move typically occurs. Correlation measures the tendency for a symbol to move in unison with the group, beta measures the amount the symbol is expected to move relative to the group and relative strength looks back at the recent past to show how the stock has been moving relative to the group.

CATALYST PHARMACEUTICAL PART (NASDAQ:CPRX) - Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including epilepsy and drug addiction. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.

SYNTA PHARMACEUTICALS CORP (NASDAQ:SNTA) - Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its research and development programs include STA-9090, an Hsp90 inhibitor that is in Phase II stage for non-small cell lung cancer and gastrointestinal stromal tumors, as well as in Phase I for hematologic cancers and solid tumors; Elesclomol, an oxidative stress inducer that is in Phase I/II stage for solid and hematologic cancers; and STA-9584, a vascular disrupting agent, which is in preclinical development for cancer. The companys programs also include Apilimod (STA-5326), an oral IL-12/23 inhibitor, which is in Phase IIa stage for rheumatoid arthritis; and Oral CRACMchannelinhibitor that is in preclinical development for autoimmune diseases and respiratory conditions. It has a partnership with Hoffmann-La Roche for the development of CRACM inhibitors; and a joint collaboration with The Multiple Myeloma Research Foundation Inc. for the clinical development of ganetespib in patients with multiple myeloma. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

OREXIGEN THERAPEUTICS INC (NASDAQ:OREX) - Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The companys Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.

CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) - Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders, and diseases caused by infectious organisms. Its precision targeted immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates, and immunomodulators to create disease-specific drug candidates. The company offers Rotarix for the treatment of rotavirus infection. Its clinical development programs include CDX-110, which is in Phase IIb clinical trail for the treatment of glioblastoma multiforme; CDX-011 that is in Phase II clinical trial to treat metastatic melanoma and breast cancer; and CDX-1307, a Phase I clinical trial product for treating colorectal, bladder, pancreas, ovarian, and breast tumors, as well as CDX-1401 and CDX-1135, which are in Phase I/II clinical trials for the treatment of multiple solid tumors and renal diseases respectively. The companys preclinical product candidates comprise CDX-301 for treating cancer, and autoimmune diseases and transplants; CDX-1127 for immuno-modulation and multiple tumors; CDX-014 to treat renal and ovarian cancer; and CDX-1189 for renal diseases. It has collaborative partnership agreements with GlaxoSmithKline plc; Pfizer Inc.; Vaccine Technologies, Inc.; and TopoTarget A/S, as well as research collaboration and licensing agreements with Medarex, Inc.; Alteris Therapeutics, Inc.; 3M Company; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company was founded in 1983 and is headquartered in Needham, Massachusetts.

ISHARES NASDAQ BIOTECH INDX (NASDAQ:IBB) - ISHARE NQ BIOTCH

PAR PHARMACEUTICAL COS INC (NYSE:PRX) - Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. engages in the development, manufacture, and distribution of generic and branded drugs in the United States. Its principal generic products include Metoprolol succinate ER, Sumatriptan succinate injection, Meclizine Hydrochloride, Clonidine TDS, Dronabinol, Cabergoline, Propranolol HCl ER, Cholestyramine Powder, Methimazole, Megestrol oral suspension, Tramadol HCl and acetaminophen tablets, Fluticasone, Ibuprofen Rx, and various amoxicillin products. The company offers its drugs in solid oral dosage forms, such as tablets, caplets, and two-piece hard-shell capsules; oral suspension products; nasal spray products; products delivered by injection; and products in the semi-solid form of a cream and a transdermal patch. Its brand products include Megace ES drugs for the treatment of anorexia, cachexia, or any unexplained significant weight loss in patients with a diagnosis of AIDS; Nascobal Nasal Spray, a prescription vitamin B12 treatment indicated for maintenance of remission in certain pernicious anemia patients, as well as a supplement for various B12 deficiencies; and Androgel, a testosterone gel indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Par Pharmaceutical plans to launch Zuplenz, an oral soluble thin film formulation for the prevention of chemotherapy induced nausea and vomiting, and post-operative nausea and vomiting; and Oravig, a miconozole antifungal therapy for the treatment of oropharyngeal candidiasis. It markets its products to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, managed health care organizations, mail order accounts, drug distributors, nursing homes, hospitals, clinics, government agencies, and pharmacy benefit management companies. The company was founded in 1978 and is based in Woodcliff Lake, New Jersey.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net

N@N

DRUGS - GENERIC Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.